Glucagon-like peptide 1 receptor agonists for treatment of steatotic liver disease in patients with Type 2 diabetes mellitus: growing evidence but not yet ...
reviewer4you.com
Su1567 THE MOLECULAR BASIS OF THYROID HORMONE RESCUE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN MICE
EP19 IMPROVING TRIAGE AND CARE FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AT A VA PRIMARY CARE CLINIC
Su1566 DISEASE PROGRESSION IN PATIENTS WITH METABOLIC DYSFUNCTIONASSOCIATED STEATOTIC LIVER DISEASE USING PAIRED LIVER BIOPSY
Su1609 SEVERE OBESITY IS ASSOCIATED WITH WORSE OUTCOMES THAN LEAN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A POPULATION-BASED COHORT STUDY ...
Su1562 RELEVANCE OF MAST CELLS IN THE ADVANCED STAGES OF METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE
Su1532 ASSOCIATIONS BETWEEN EXERCISE PATTERNS AND CLINICAL OUTCOMES IN A PROSPECTIVE COHORT OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC ...
Su1607 INVESTIGATION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN AN UNDERINSURED AND LOWSOCIOECONOMIC RESIDENT CLINIC; A CROSS-SECTIONAL ...
100 PARENTAL OBESITY AT PREGNANCY WITH RISK OF METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE IN YOUNG ADULT OFFSPRING
Sa1551 PREVALENCE OF STEATOTIC LIVER DISEASES AND ASSOCIATED RISK FACTORS IN SEXUAL AND GENDER MINORITIES IN THE UNITED STATES